UNICREDIT BANK/CALL/MODERNA/180/0.1/19.03.25 | Real-time BOERSE MUENCHEN 08:41:36 23/05/2024 BST | ||
| 2.64 EUR | -0.75% |
|
| Current month | +280.00% | ||
| 1 month | +375.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 2.64 | -0.75% |
| 22/05/24 | 2.66 | +68.35% |
| 21/05/24 | 1.58 | +7.48% |
| 20/05/24 | 1.47 | +25.64% |
| 17/05/24 | 1.17 | -1.68% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 08:41 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| WKN | HD4WM1 |
| ISIN | DE000HD4WM16 |
| Date issued | 22/04/2024 |
| Strike | 180 $ |
| Maturity | 19/03/2025 (301 Days) |
| Parity | 10 : 1 |
| Emission price | 0.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.66 € |
|---|---|
| Lowest since issue | 0.49 € |
| Spread | 0.12 € |
| Spread % | 4.51% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- Warrant
